This is an old revision of this page, as edited by Applegoddess (talk | contribs) at 19:53, 3 September 2005 (added more info from cymbalta prescribing info (pi.lilly.com/us/cymbalta-pi.pdf)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 19:53, 3 September 2005 by Applegoddess (talk | contribs) (added more info from cymbalta prescribing info (pi.lilly.com/us/cymbalta-pi.pdf))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)|
| |
| IUPAC chemical name | |
| CAS number ? |
ATC code ? |
| Chemical formula | C18H19NOS, HCl |
| Molecular weight | 333.38 |
| Bioavailability | ? |
| Metabolism | ? |
| Elimination half-life | 8-17 hours |
| Excretion | ? |
| Pregnancy category | C (USA) |
| Legal status | Prescription only (USA) |
| Routes of administration | Oral |
Duloxetine hydrochloride (brand name: Cymbalta) is a medically used drug that primarily targets major depressive disorders (MDD), pain related to diabetic peripheral neuropathy and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(S)-N-methyl-3-(1-naphthyloxy)-2-thiophenepropanamine, it is a potent dual inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors.
Furthermore, duloxentine lacks affinity for monoamine receptors within the central nervous system. While there is limited data available regarding the pharmacokinetic profile of duloxetine in humans, its half-life is reported to be 10 to 15 hours.
Duloxentine is also approved by the FDA for the treatment of diabetic neuropathy.
External links
- Manufacturer website
- Cymbalta Antidepressant Medication
- Duloxetine - medlineplus.org
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |